Enzalutamide (Indenza) is an innovative, highly effective antineoplastic medication designed for the pathogenetic treatment of prostate malignancies at various stages of the disease process. Its active pharmaceutical ingredient, enzalutamide, belongs to the pharmacological class of second-generation non-steroidal antiandrogens and acts as a potent, selective inhibitor of the androgen receptor signaling pathway. The mechanism of action is comprehensive and based on competitive binding to the active site of androgen receptors on target cells, complete inhibition of their nuclear translocation, and blockage of the receptor complex's interaction with tumor DNA. By shutting down this critical hormonal pathway, Indenza terminates the stimulating influence of male sex hormones (testosterone and dihydrotestosterone) on tumor tissue, which triggers apoptosis of cancer cells, induces a significant reduction in PSA levels, and provides sustained inhibition of disease progression.
Manufacturer: Aprazer Healthcare Private Limited. This product is manufactured under strict licensing and technological control by one of India's leading pharmaceutical companies, specializing in the high-tech oncology sector in full compliance with GMP quality standards. Indenza is globally recognized as a standard of care for metastatic and non-metastatic castration-resistant prostate cancer, as well as metastatic hormone-sensitive prostate cancer, delivering a statistically significant extension of overall patient survival, delaying the need for cytotoxic chemotherapy, and preserving a high quality of life.
Key Advantages:
- ✅ Triple Mechanism of Inhibition: Blocks androgen binding, prevents nuclear translocation of the receptor, and halts its interaction with tumor DNA.
- ✅ Overcoming Resistance: Highly effective in clinical situations where first-generation antiandrogens (such as bicalutamide or flutamide) have failed due to tumor resistance.
- ✅ Oral Convenience: The soft capsule formulation enables patients to receive advanced oncological care on an outpatient basis, eliminating the need for frequent clinic visits for injections.